Alnylam Pharmaceuticals Surges to 328th in Trading Volume with $266 Million Day Amid AMVUTTRA Approval in Europe

On June 12, 2025, Alnylam Pharmaceuticals (ALNY) saw a significant surge in trading volume, reaching $266 million, marking a 94.48% increase from the previous day. This substantial rise placed Alnylam at the 328th position in terms of trading volume for the day. The stock price of Alnylam also experienced a notable increase, rising by 2.04%.

Alnylam's recent approval of AMVUTTRA in Europe represents a significant milestone, validating the potential of the RNAi platform in cardiovascular therapeutics. This approval underscores the company's strong execution and innovation in the ATTR-CM space, driving a positive outlook for the future.

The European Commission has approved Amvuttra for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). This expansion of the label for Amvuttra is a testament to the efficacy and safety of the drug in treating this debilitating condition.

Alnylam Pharmaceuticals, Inc. (ALNY) announced that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy. This approval is a significant achievement for the company, as it expands the therapeutic options available for patients suffering from this condition.

Alnylam Pharmaceuticals has received European Commission approval for its RNAi therapeutic, AMVUTTRA, to treat adult patients with transthyretin amyloidosis with cardiomyopathy. This approval is a breakthrough in the treatment of ATTR amyloidosis, as it shows a 36% lower mortality rate in EU patients. The approval of AMVUTTRA as the first RNAi therapy for this indication is a significant achievement for Alnylam and the broader biotech industry.